Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO
Brief Summary: Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye.

The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK).

This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.


Options:
A: Inclusion Criteria:

* CRVO must have occurred within the past 6 months and be associated with macular edema determined by OCT.
* Vision in the study eye corresponding to between approximately 20/50 to 20/400 and better than or equal to approximately 20/200 in the fellow eye.

Exclusion Criteria:

* Presence of signs of old branch retinal vein occlusion (BRVO) or CRVO in the study eye or any other retinal vascular disease including diabetic retinopathy.
* Vitreous hemorrhage except breakthrough hemorrhage from intraretinal hemorrhage.
* Prior pan retinal photocoagulation (PRP) or sector scatter photocoagulation.
B: Inclusion Criteria:

* Patients must have histologically or cytologically confirmed non-small cell lung cancer EXCEPT squamous cell carcinoma; mixed tumors will be categorized by the predominant cell type unless small cell elements are present in which case the patient is ineligible; cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy
* Patients must have advanced NSCLC (stage IIIB with malignant pleural effusion or stage IV or recurrent disease)
* Patients must have measurable or non-measurable disease
* ECOG performance status 0 or 1
* Patients must not have known central nervous system (CNS) metastases; a head CT is required within 4 weeks prior to study entry; (MRIs are also acceptable)
* Patients must not have received prior systemic chemotherapy at any time
* ANC \>= 1500/mm\^3
* Platelets \>= 100,000/mm\^3
* Total bilirubin =\< 1.5 mg/dl
* Transaminases =\< 5 x ULN
* Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN)
* Urine dipstick for proteinuria of less than 1+ (i.e., either 0 or trace); if urine dipstick is \>= 1+ then a 24 hour urine for protein must demonstrate \< 500 mg of protein in 24 hours to allow participation in the study; note: urinalysis is also acceptable
* Patients must have INR =\< 1.5 and a PTT no greater than upper limits of normal within 1 week prior to randomization
* Pregnant and lactating women are excluded from the study
* Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study
* Patients must not have had immuno, hormonal or radiation therapy within 3 weeks prior to entering the study; those who have not recovered from adverse events due to agents administered more than 3 weeks earlier are ineligible
* Patients must not have ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Patients must have no history of thrombotic or hemorrhagic disorders
* Patients with history of hypertension must be well-controlled (\< 150/100) on a stable regimen of anti-hypertensive therapy
* Patients must not be receiving chronic daily treatment with aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory agents known to inhibit platelet function; treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and/or cilostazol (Pletal) is also not allowed
* Patients must not have serious non-healing wound ulcer, or bone fracture, or major surgical procedure within 21 days prior to starting treatment
* Patients must not be on therapeutic anticoagulation; prophylactic anticoagulation of venous access devices is allowed; caution should be taken on treating patients with low dose heparin or low molecular weight heparin for DVT prophylaxis during treatment with bevacizumab as there may be an increased risk of bleeding
* Patients with a history of gross hemoptysis (defined as bright red blood of a 1/2 teaspoon or more) will be excluded from this trial
C: Inclusion Criteria:

* Active, subfoveal choroidal neovascularization (CNV)
* Fibrosis \< 50% of total lesion area
* Visual acuity (VA) 20/25-20/320
* Age ≥ 50 yrs
* At least 1 drusen (\>63μ) in either eye or late AMD in fellow eye

Exclusion Criteria:

* Previous treatment for CNV in study eye
* Other progressive retinal disease likely to compromise VA
* Contraindications to injections with Lucentis or Avastin
D: Inclusion Criteria:

* glaucoma
* undergoing trabeculectomy
* 21 years of age or older

Exclusion Criteria:

* pregnancy or lactation
* any condition the investigator believes would impose a significant hazard to the patient if investigational therapy were initiated
* history of ocular surface disease
* cataract surgery in the past 6 months
* history of active inflammatory, infectious or idiopathic keratitis

Answer: A